Program
IBI112
A development code. Also written as “Period 2 IBI112 dose 3”, “Period 1 IBI112 dose 1” and “Period 1 IBI112 dose 2”.
Its studies are mostly in Psoriasis · Colitis, Ulcerative, led by Innovent Biologics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 61 open or running | phase 3since Dec 1, 2022 | Aug 3, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 3, 2020First study: phase 1 study in Healthy SubjectsFirst studyNCT04511624 · 46 enrolled · China
- Aug 5, 2021Phase 2 study in PsoriasisNCT05003531 · 250 enrolled · China
- May 6, 2022Phase 2 study in Colitis, UlcerativeNCT05377580 · 150 enrolled · China
- Dec 1, 2022Phase 3 study in PsoriasisNCT05645627 · 500 enrolled · China
- Sep 13, 2023Phase 3 study in PsoriasisNCT06049810 · 566 enrolled · China
- Nov 24, 2025Phase 3 study in PsoriasisNCT07265284 · 104 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07265284Psoriasis · China | 3 | Recruiting | Sep 30, 2026 | 104 |
| NCT06049810Psoriasis · China | 3 | Completed | Apr 29, 2025 | 566 |
| NCT05645627Psoriasis · China | 3 | Completed | Aug 9, 2023 | 500 |
| NCT05377580Colitis, Ulcerative · China | 2 | Completed | Jun 21, 2024 | 150 |
| NCT05003531Psoriasis · China | 2 | Completed | Mar 25, 2022 | 250 |
| NCT04511624Healthy Subjects · China | 1 | Completed | Jul 22, 2022 | 46 |
How it is read
Names in the registry
- “IBI112”, 7 entries
- “Period 2 IBI112 dose 3”, 1 entry
- “Period 1 IBI112 dose 1”, 1 entry
- “Period 1 IBI112 dose 2”, 1 entry
- “Period 2 IBI112 dose 4”, 1 entry
Codes read as this program: IBI112.
Conditions, from the studies’ own filings
- Psoriasis, 4 studies
- Colitis, Ulcerative, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.